What the FDA labels say about taking them together
Etoposide and ondansetron
Ondansetron's FDA label of January 8, 2026 names etoposide in its drug interactions section; the etoposide labels PlainMeds reads (3) do not name ondansetron. The ondansetron label: “Chemotherapy Carmustine, etoposide, and cisplatin do not affect the pharmacokinetics of ondansetron.”
Check it at the source: the etoposide FDA label on DailyMed (effective September 14, 2023, Hikma Pharmaceuticals USA Inc.); the ondansetron FDA label on DailyMed (effective January 8, 2026, Glenmark Pharmaceuticals Inc., USA).
What does the etoposide label say about ondansetron?
Etoposide's label (effective September 14, 2023) and its 2 other brand-application labels do not name ondansetron in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Etoposide), Hikma Pharmaceuticals USA Inc., effective September 14, 2023 (SPL set 6dfedeff-a807-4405-a482-2f7109ad31c9), via openFDA; the full label on DailyMed
What does the ondansetron label say about etoposide?
Ondansetron label, drug interactionsChemotherapy Carmustine, etoposide, and cisplatin do not affect the pharmacokinetics of ondansetron.
Source: FDA drug label (Ondansetron), Glenmark Pharmaceuticals Inc., USA, effective January 8, 2026 (SPL set eee5217a-eba8-463a-812d-bf3c66f0934f), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Etoposide | Ondansetron | |
|---|---|---|
| Labeled for | Lung cancer | Nausea and vomiting |
| Boxed warning | Yes | No |
| Pharmacy cost (NADAC) | n/a | $0.0582 per tablet 4 mg tablet |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once